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ORIGINAL ARTICLE
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Abstract
Background. our aim was to define predictors of late radiation-induced lung injury (RILI) in Hodgkin’s lymphoma 
(HL) survivors treated with bleomycin-containing chemotherapy and radiotherapy. Material and methods. Eighty 
consecutive patients treated with chemotherapy and subsequent supradiaphragmatic radiation therapy for HL were 
retrospectively reviewed for symptoms and/or radiological signs of RILI. Median patient age was 26 years (range 14–55). 
Left, right, and total lung dosimetric parameters along with clinical, disease, and treatment-related characteristics were 
analyzed. Multivariate logistic regression analyses were performed. a receiver operator characteristic (RoC) curve 
analysis was performed to find possible cutoff values dividing patients into high- and low-risk groups. Results. seven of 
80 (9%) patients had lung disease at baseline. four of 80 (5%) had toxicity after chemotherapy and before the beginning 
of radiotherapy. These patients were excluded from further evaluation. at a median time of 10 months (range 9–18), 
9/69 patients (13%) developed lung radiological changes on computed tomography (CT) after treatment. four of nine 
patients were diagnosed RTog grade  2. on multivariate analyses, left-lung V30 (p  0.004, oR  1.108 95% CI 
1.033–1.189) and total-lung V30 (p  0.009, oR  1.146 95% CI 1.035–1.270) resulted to be predictors of lung CT 
changes with a cutoff value of 16% and 15%, respectively. When only symptomatic RILI was considered a left-lung 
V30 cutoff value of 32% was estimated. Conclusion. Bleomycin and RT may cause lung injury in a small, but significant 
fraction of HL patients. Left-lung V30 predicts the risk of developing asymptomatic or symptomatic RILI after sequential 
chemo-radiotherapy.
The gold standard treatment of early stage Hodgkin’s 
lymphoma (HL) is sequential chemo-radiation ther-
apy. a common side effect of both chemotherapy 
(CHT) and thoracic irradiation is lung toxicity. CHT 
regimens incorporate bleomycin, which may cause 
severe lung injuries ranging from hypersensitivity 
pneumonitis and bronchiolitis obliterans organizing 
pneumonia to acute interstitial pneumonia and pro-
gressive pulmonary fibrosis. Bleomycin-induced lung 
injury may occur at a rate in the range of 3–20% [1]. 
similarly, radiotherapy (RT) involving the thoracic 
region may determine radiation-induced lung injury 
(RILI). an extensive literature deals with factors 
capable of predicting early or late RILI, mainly severe 
radiation pneumonitis, for patients receiving RT for 
non-small cell lung cancer [2–4]. studies on the 
evaluation of dosimetric predictors for mild to mod-
erate radiation-induced pulmonary toxicity in breast 
cancer are also available [5,6]. Compared with lung 
or breast cancer patients, HL patient population is 
generally characterized by lower age, better perfor-
mance status, different smoking history in addition 
to different CHT regimens and lower radiation 
doses prescribed. all these factors lead to a low inci-
dence (5–10%) of clinically significant symptomatic 
pneumonitis in HL cohorts [2]. Limited data are 
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available on dosimetric predictors for RILI in HL 
patients. specific studies on RILI in HL patients are 
those by Koh et al. and by fox et al. [7,8] focused 
on acute radiation pneumonitis, while Ng et al. [9] 
evaluated pulmonary function decline in HL patients 
receiving combined modality therapy. However, 
bleomycin-containing CHT along with lower radia-
tion doses inherent to HL radiation treatments may 
be responsible of late-phase subclinical RT-induced 
injury such as fibrosis with radiological lung density 
changes detectable by computed tomography (CT). 
Imaging appearance of radiation lung fibrosis may 
manifest itself as volume loss, consolidation and trac-
tion bronchiectasis and can be seen even without any 
prior radiation pneumonitis [10]. fibrosis, even if 
asymptomatic, may decrease lung compliance thus 
reducing the patient’s reserve needed to deal with 
future cardiopulmonary stresses [2]. furthermore, it 
has been hypothesized that subclinical lung damage 
could be indirectly responsible of secondary cardiac 
damage [11]. as a consequence, the knowledge of 
clinical and/or dosimetric factors predicting asymp-
tomatic RILI is of great importance for HL patients 
characterized by high cure rates and prolonged sur-
vival. Recently, emerging radiation techniques for 
HL management [12] considerably increase sparing 
of organs at risk and control over dose distribution, 
thus amplifying the clinical relevance of the determi-
nation of predictive factors to be used for an effective 
RT planning.
The aim of this study was to quantify the 
incidence of symptomatic and asymptomatic lung 
injuries and to identify clinical and dosimetric 
parameters that correlate with the risk of late RILI 
development in a cohort of 80 HL patients treated 
with bleomycin-containing CHT regimens and RT.
Material and methods
Patients and treatments
Clinical and dosimetric records of 80 consecutive 
patients with HL were retrospectively reviewed for 
late RILI events. all patients received CHT and sub-
sequent supradiaphragmatic radiation therapy at our 
Radiation oncology Department from November 
2001 to october 2009. Median patient age was 26 
years (range 14–55). Median follow-up was 80 
months (range 53–135).
CHT consisted of 4–6 cycles either of VEBEP 
(vinblastine 6 mg/m2 i.v. day 1 and 15, etoposide 80 
mg/m2 i.v. days 1–3 and 15–17, bleomycin 10 mg/m2 
i.v. day 1 and 15, epidoxorubicin 40 mg/m2 i.v. day 
1 and 15, and prednisone 40 mg/m2 p.o. days 1–5 
and 15–19) or aBVD (doxorubicin 25 mg/m2, bleo-
mycin 10 mg/m2, vinblastine 6 mg/m2, and dacarba-
zine 375 mg/m2, all drugs i.v. and administered day 
1 and 15 every 28 days). Both CHT settings provide 
the same bleomycin dosage.
Clinical target volume (CTV) included the nodal 
sites involved at the time of diagnosis in patients with 
disease stage I–II [13], and the residual disease and/
or the bulky site in patients with disease stage III–IV. 
Planning target volume (PTV) included CTV plus a 
1-cm margin. all patients were treated with full 
three-dimensional (3D) free-breathing CT-based 
radiation treatment planning as described in detail in 
previous publications [13,14]. Radiation therapy 
was administered using 6–20 MV photon beams 
from a linear accelerator with anteroposterior- 
posteroanterior fields. a total dose from 30 to 45 gy 
was prescribed. Daily fraction size ranged between 
1.5 gy and 1.8 gy. 3D conformal plans were gener-
ated using a commercial treatment planning system 
(Xio 4.64, Elekta CMs) with the multigrid super-
position dose calculation algorithm (grid spacing 
0.4 cm) for heterogeneous tissues.
for all patients, the left and right lung tissues (LL 
and RL) were retrospectively contoured by the same 
radiation oncologist following RTog 1106 recom-
mendations [15]. The total lung (TL) taken as a 
single, paired organ was also considered.
Dosimetric parameters for lung structures were 
extracted from the cumulative dose-volume histo-
grams (DVHs). Dosimetric parameters included: the 
dose to 2% and to 50% of the volume (D2%, D50%), 
and the percentage volume exceeding X gy (Vx) in 
increment of 5 gy. We corrected the dosimetric 
parameters for the different dose per fraction size 
using an a/b ratio of 4 for the lung [16].
RILI evaluation
all patients have been monitored for lung disease/
injury as part of clinical routine during CHT, after 
CHT before RT, and after RT. Baseline and follow-up 
evaluations consisted of history and physical exami-
nation along with periodic (every 6 months for the 
first 2 years, and yearly thereafter) total body CT 
scans. follow-up visits were planned every 3 months 
for the first year, then every 6 months for the next 2 
years, and once a year thereafter. The compliance of 
the patients to the follow-up schedule was good with 
all patients who had undergone at least five visits and 
two CT scans in the first 2 years.
signs and symptoms of RILI were scored accord-
ing to the RTog late toxicity scoring system [17] 
into the following groups:
Grade 1: asymptomatic or mild symptoms  
(dry cough); slight radiographic appearances
Grade 2: Moderate symptomatic fibrosis or 
pneumonitis (severe cough); low grade fever; 
patchy radiographic appearances
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Grade 3: severe symptomatic fibrosis or  
pneumonitis; dense radiographic changes
Radiological lung density changes post-CHT-RT 
were evaluated on follow-up CT scans using the 
treatment planning CT as base-line comparison. all 
the CT scans were retrospectively reviewed by a radi-
ologist. Time to RILI was computed from the begin-
ning of treatment to the first symptom and/or 
radiological signs.
any pretreatment lung disease (e.g. asthma), or 
any bleomycin-related lung toxicity along with 
comorbidities (preexisting cardiac abnormalities, 
hypertension, hypercholesterolemia and diabetes) as 
well as smoking history were recorded for each 
patient. Pretreatment elevated C-reactive protein 
(CRP) and lactate dehydrogenase (LDH) levels over 
normal limits were also recorded [18,19].
Statistical analysis
statistical analysis was performed first for patients 
with symptoms, next for patients with radiological 
signs of RILI, thus including the former. accord-
ingly, the categories “symptomatic RILI” and “CT 
changes” were defined. Patient, disease and treat-
ment-related characteristics were examined accord-
ing to the development of “symptomatic RILI” or 
“CT changes” by univariate statistical methods: 
categorical variables were expressed as percentages 
and tested by Pearson’s c2-test or fisher’s exact 
test when appropriate; the median and the range 
were used to describe all continuous variables and 
Mann-Whitney u-test was employed for analyzing 
them.
Multivariate logistic regression analysis was per-
formed on those parameters which resulted signifi-
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gi(x)  b0  b1xi1  b2xi2  … bnxin (2)
where m is the number of patients, x1, x2, …, xn  
represent different input variables and b0, b1, …, bn 
are the corresponding regression coefficients. 
for the selection of variables, a stepwise method 
(Wald-Enter method, p  0.05 for entry into the 
model and p  0.10 for removal from the model) 
was performed. a receiver operator characteristic 
(RoC) curve analysis was performed to find pos-
sible discrimination values dividing patients into 
high- and low-risk groups. The discrimination value 
on the RoC curve was determined by Youden’s J 
statistic. a non-parametric paired test (Wilcoxon 
signed rank test) was used to compare LL and RL 
dosimetric parameters. statistical analysis was per-
formed with sPss 18.0 and MedCalc statistical 
software.
Results
seven of 80 (9%) patients had some type of lung 
disease or CT appearance of radiological findings 
before CHT treatment while four of 73 (5%) had 
bleomycin-related lung toxicity after CHT and before 
beginning RT. These patients were excluded from 
further evaluations. Characteristics of the 69 patients 
eligible for analysis are shown in Table I.
at a median time of 10 months, nine patients 
(13%) developed radiological changes on CT. 
The CT changes occurred in three patients at 
Table I. Patient, disease and treatment characteristics.
Median Range
Age (y)   26 (14–55)
Left lung volume (cm3) 1247 (664–2793)






Nodular sclerosis 49 72
Mixed cellularity 17 25










Radiotherapy dose delivered (Gy)
28.5–30.0 28 41
30.1–32.0 29 43
32.1–36.0  8 12
36.1–45.0  3  4




Diabetes  1  1
Hypertension  2  3
Hypercholesterolemia  0  0
Cardiac comorbities  5  7
Elevated CRP 48 70
Elevated LDH 19 27
 aBVD, doxorubicin, bleomycin, vinblastine and dacarbazine; 
CRP, C-reactive protein; LDH, lactate dehydrogenase; VEBEP, 
vinblastine, etoposide, bleomycin, epidoxorubicin.
*There can be multiple factors simultaneously.
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9 months after treatment, in two patients at 10 
months, in one at 11 months, in one at 15 months, 
and in two at 18 months. four patients were symp-
tomatic: one patient was diagnosed with severe 
symptomatic fibrosis showing dense radiographic 
changes (grade 3), three cases developed grade 2 
RILI (one slight radiological changes with severe 
cough and two moderate symptomatic fibrosis with 
patchy radiographic appearances). five patients 
developed slight CT radiological changes without 
symptoms (grade 1).
Complete descriptive statistics are reported in 




Cases of grades 2 and 3 symptomatic RILI (four 
patients) were grouped together in the analyses and 
compared with asymptomatic patients. The univari-
ate analysis didn’t show significant differences in the 
distribution of clinical and disease factors between 
symptomatic and asymptomatic patients (Table sI). 
Results of univariate analysis for dosimetric param-
eters of LL, RL and TL are reported in Table sII. 
TL D2% and LL dosimetric parameters (D2%, V25 
and V30) resulted significantly correlated to symp-
tomatic RILI. applying multivariate logistic regres-
sion to potential predictors, LL-V30 (p  0.014, 
oR  1.164 95% CI 1.031–1.312) resulted to be the 
only independent predictor of the risk of symptom-
atic RILI (Table II). The result of RoC analyses 
(figure 1a) was a discrimination value of 32% 
(auC  0.87, 95% CI 0.76–0.94).
for LL-V30, figure 2a shows the response curve 
calculated from Equation 1 and compared with the 
fraction of complications observed in the data 
grouped into quartiles.
CT radiological density changes
When we considered all CT radiological density 
changes (i.e. any grade of RILI, nine patients) as 
outcome, the univariate analysis showed once again 
no significant difference in the distribution of clinical 
parameters between patients who developed CT 
changes and patients who did not (Table sI). Results 
of univariate analysis for dosimetric factors of LL, 
RL and TL are shown in Table sII. Dosimetric 
parameters for TL (D2%, V25 and V30) along with 
dosimetric parameters for LL (D50%, V05-V30) 
resulted significantly correlated to CT changes. 
applying multivariate logistic regression to TL and 
LL potential predictors, TL-V30 (p  0.009, 
oR  1.146 95% CI 1.035–1.270) and LL-V30 
(p  0.004, oR  1.108 95% CI 1.033–1.189) were 
the only independent predictors of CT changes, 
respectively. Results of multivariate logistic regres-
sion are reported in Table II.
The results of RoC analyses (figure 1b and c) 
were a discrimination value of 15% (auC  0.79, 
95% CI 0.68–0.88) for TL-V30 and of 16% 
(auC  0.80, 95% CI 0.69–0.89) for LL-V30.
for TL-V30 and LL-V30, figure 2b and c show 
the response curves calculated from Equation 1 
and compared with the fraction of complications 
observed in the data grouped into quartiles.
In order to check if the obtained results on the 
LL were due to CTV localization and, consequently, 
to an asymmetric irradiation of the different lungs, 
we compared LL and RL dosimetric parameters. By 
analyzing either the entire cohort of patients or only 
the group of patients who developed CT changes 
no significant difference was found between LL ver-
sus RL dosimetric parameters. These results imply 
that both lungs were equally irradiated. Moreover, 
the spatial distribution of CT changes was uniformly 
distributed between left and right lungs.
Discussion
Bleomycin is an effective antineoplastic drug and 
it has been used successfully to treat a variety of 
malignancies, including HL. Nonetheless, bleomycin 
administration may result in lung inflammation 
that can progress to fibrosis. The mechanism of 
bleomycin-induced lung injury is not entirely 
clear, but it is likely to include components of 
oxidative damage, relative deficiency of the deacti-
vating enzyme bleomycin hydrolase, and elaboration 
of inflammatory cytokines leading to endothelial 
Table II. Results of the multivariate analyses for symptomatic radiation-induced lung injury (RILI) and 
CT changes.
Endpoint Parameter Estimated coefficient sE p-value oR 95% CI
Symptomatic 
RILI
Left-lung V30 (%) 0.151 0.061 0.014 1.164 1.031–1.312
constant 27.312 2.386 0.002
CT changes Total-lung V30 (%) 0.136 0.052 0.009 1.146 1.035–1.270
constant 24.8528 1.380 0.001
CT changes Left-lung V30 (%) 0.103 0.036 0.004 1.108 1.033–1.189
constant 24.257 1.069 0.001
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figure 2. Comparison of risk curves obtained by logistic regression 
model with the fraction of complications from the data grouped 
in quartiles for: (a) LL-V30 for symptomatic RILI (4 events over 
69 patients), (b)–(c) TL-V30 and LL-V30 for radiological CT 
changes (nine events over 69 patients). The error bars are the 
standard deviation calculated from the data.
figure 1. Receiver operating characteristic curve and histogram 
of outcome distribution for discrimination value definition: 
(a) LL-V30 for symptomatic RILI; (b) TL-V30 for radiological 
CT changes; (c) LL-V30 for radiological CT changes. The dotted 
line represents the discrimination value.
irradiation can even further potentiate bleomycin-
induced lung toxicity [21]. However, a large fraction 
of patients experience sub-clinical RILI [2].
Indeed, RILI generally manifests itself with 
two distinct clinical and pathologic phases: an early 
phase of transient inflammation and a later phase of 
asymptomatic chronic fibrosis. Pulmonary fibrosis is 
a consequence of the repair process by the injured 
tissue within the irradiated lung regions. It follows 
release of chemotactic factors for fibroblast including 
transforming growth factor-beta, fibronectin and 
platelet derived growth-factor. Patients who never 
experience symptomatic radiation pneumonitis may 
present with fibrosis some time later [10]. Data on 
damage of the lung vasculature [20]. In early stage 
HL patients, bleomycin-containing polichemother-
apy is sequentially administered before irradiation. 
RILI in HL is well documented [7,8]. Mediastinal 
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potential biological mechanism as well as its clini-
cal meaning. However, we may hazard that the 
intrinsic difference between right and left lung (i.e. 
different numbers of lobes and size) could be a 
possible explanation for this finding. Remarkably, 
Wiegman et al. [22] show in rats that LL irradia-
tion has the most significant impact on lung toxic-
ity evaluated using lung function and CT density 
as endpoints.
The lungs have been usually considered as a 
unique organ unit in dosimetric studies. some 
authors, in lung or breast cancer patients’ studies, 
separately examined the effects of the radiation dose 
in relation to the ipsilateral and contralateral lung 
with respect to tumor location [2,5,23]. In a cohort 
of breast cancer patients including mastectomized 
patients who received chest wall RT, Blom-goldman 
et al. [5] found a trend for the relation between ipsi-
lateral lung V30 and density changes. unfortunately, 
none of the above studies distinguished between left 
and right tumor position and consequently between 
right and left lung. The only study recording these 
data is that by fay et al. [24] who have found a trend 
between LL irradiation and the development of radi-
ation pneumonitis. Moreover, it has been suggested 
that coirradiation of the heart may influence lung 
function due to the physiologic link between the lung 
and the cardiovascular system [11,25]. We can spec-
ulate that the significance for LL-V30, particularly 
stronger in symptomatic patients, may be in some 
way related to the irradiation of the heart.
It should be emphasized that our findings are the 
result of late pulmonary toxicity also evaluated by a 
high sensitive radiological method such as high- 
resolution CT which prevents the comparison with 
previous studies on lung toxicity in HL patients. In 
addition, we have taken into account the combined 
effect of bleomycin and radiation which prevents the 
comparison with data on RILI derived from patient 
settings other than HL. as with any retrospective 
analysis, our study had some limitations. for exam-
ple, for most patients, we did not have data regarding 
pulmonary function. furthermore, it is important to 
stress the relative small size of the analyzed cohort 
and a consequent low number of events. We need to 
continue to collect data in order to develop a more 
complete NTCP analysis.
In conclusion, sequential bleomycin-based CHT 
and radiation therapy may cause lung injury in a 
small, but significant fraction of HL patients. Through 
dosimetric analyses on lungs, also considered indi-
vidually, we identified the LL as a critical volume and 
more precisely LL-V30 as a predictive factor of the 
risk of developing both asymptomatic and symptom-
atic late RILI. We defined threshold values for LL-V30 
of 32% for symptomatic RILI and of 16% for CT 
radiological changes, respectively. The inclusion of 
RILI have been mainly obtained from lung cancer 
settings and were often derived from patients with an 
in situ lung cancer [2]. at the same time late effects 
such as pulmonary fibrosis have been less investi-
gated despite the fact that the latter is important for 
long-term quality of life and could result in future 
respiratory insufficiency.
It has been suggested that it might be relevant to 
develop separate predictive models for RILI in 
patients with intact lungs and also explicitly analyze 
symptomatic, functional and radiographic endpoints 
separately [2].
Volume of TL exceeding 20 and 30 gy, along 
with mean lung dose (MLD), are well established 
predictors of RILI being V20 and MLD the most 
commonly reported predictors in the literature on 
lung and breast cancer. Dosimetric predictors in HL 
patients were less extensively studied. However, 
TL-V20 and MLD were also identified as predictive 
factors for acute radiation pneumonitis in HL 
patients in the studies by Koh et al. and by fox et al. 
[7,8]. a V20 of 36% and a MLD of 14 gy were 
found to be predictive of clinically significant pneu-
monitis (RTog grade 2) by Koh et al. while slightly 
lower values (V20 of 33.5% and a MLD of 13.5 gy) 
were obtained by fox et al. for RTog grade 1–3.
In our cohort, 5% of patients had lung toxicity 
after CHT and before the start of RT. This incidence 
is in agreement with that reported in literature [1]. 
furthermore, the incidence of lung toxicity in a 
series of HL patients treated at our institution with 
CHT alone was 5% (unpublished data).
at a median time of 10 months (range 9–18), we 
found an incidence of CT density changes of 13% 
(7% asymptomatic and 6% symptomatic). We sepa-
rately analyzed symptomatic (grade  2) patients, 
and patients with radiological signs of RILI thus 
including the former patients. None of the clinical or 
CHT-related factors was associated with the consid-
ered outcomes. The LL-V30 emerged as the only 
independent dosimetric predictor of symptomatic 
RILI with a corresponding threshold value of 32% 
(auC  0.87). Interestingly, we found a trend 
(p  0.08) for TL-V30 and a corresponding thresh-
old value of 19% (auC  0.76, 95% CI 0.65–0.86) 
basically in agreement with the results of Hernando 
et al. [2] who found a threshold of 18% for V30. 
subsequently, we considered any CT radiological 
density changes as toxicity endpoint, thus taking into 
consideration symptomatic and asymptomatic 
patients. We found TL-V30 and LL-V30 to be both 
significant predictors with lower threshold values of 
15% and of 16%, respectively.
These results suggest that the irradiation of LL 
might have a different influence on lung toxicity 
compared to the right lung. This statistical evi-
dence requires additional studies to clarify the 
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these parameters in HL treatment plan optimization 
and evaluation may reduce the long-term effect of 
radiation to the lungs. 
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